Document is current
Any future updates will be listed below
-
Authors
Safaroghli-azar, Ava
Croft, Travis
Mekonnen, Laychiluh B.
Lenjisa, Jimma
Dickel, Maja
Shrestha, Raj K.
Sita, Samyukta
Choo, Nicholas
Roach, Michael
Basnet, Sunita K.C.
Lawrence, Mitchell G.
Selth, Luke A.
Wang, Shudong https://orcid.org/0000-0001-6225-5525
-
Funding
Funding for this research was provided by:
Cancer Council NSW Project Grants (RG 23-04 and RG 25-13)
Hospital Research Foundation (C-PJ-126-Exper-2019 and 2022-CP-IDMH-019)
Flinders Foundation
Cancer Australia (2020_PdCCRS_2001432 and 2023_PCRS_0269)
National Health and Medical Research Council (2047980)
Changzhou Qianhong Biopharmaceuticals Co. Ltd., Changzhou LeSun Pharmaceuticals Ltd.
Aucentra Therapeutics Pty. Ltd.
- License Information
-
More Information
Article History
Received: 19 March 2026
Accepted: 12 June 2026
First Online: 17 June 2026
Declarations
Ethics approval and consent to participate: This study did not involve human participants, patient data, or human tissue samples. All animal procedures were approved by the University of South Australia Animal Ethics Committee (Ethics Approval Numbers: U12-23 and U33-22) and conducted in accordance with institutional guidelines for the care and use of laboratory animals.
Consent for publication: All the authors have read and approved the final manuscript and consent to its publication.
Competing interests: S. W. is founder of Aucentra Therapeutics Pty. Ltd., and Changzhou LeSun Pharmaceuticals Ltd., as well a consultant to Changzhou Qianhong BioPharma Co. Ltd. M.G.L: research collaborations with AstraZeneca and Pfizer. No potential conflicts of interests were disclosed by the other authors.
